Takeda Pharmaceutical Limited Quick Ratio (TAK) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Takeda Pharmaceutical Company Limited  (NYSE: TAK)

Takeda Pharmaceutical Limited's Quick Ratio

TAK's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 0.09 a new company low.

Within Major Pharmaceutical Preparations industry 524 other companies have achieved higher Quick Ratio than Takeda Pharmaceutical Limited in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 3933 to 4527.

Explain Quick Ratio?
How much Cash & cash equivalents TAK´s has?
What are TAK´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TAK Quick Ratio (Mar 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Mar 31 2024)
Q4
Y / Y Current Liabilities Change -16.22 % 8.5 % -16.22 % -16.22 % 8.5 %
Y / Y Cash & cash equivalent Change -23.35 % -15.01 % -23.35 % -23.35 % -15.01 %
Quick Ratio MRQ 0.09 0.1 0.09 0.09 0.1
TAK's Total Ranking # 4527 # 3933 # # #
Seq. Current Liabilities Change -16.22 % 19.36 % 0 % -16.22 % 8.5 %
Seq. Cash & cash equivalent Change -23.35 % 30.45 % 0 % -23.35 % -15.01 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 525
Healthcare Sector # 1013
Overall Market # 4527


Quick Ratio Statistics
High Average Low
0.2 0.13 0.09
(Mar 31 2021)   (Mar 31 2025)




Financial Statements
Takeda Pharmaceutical Limited's Current Liabilities $ 28,661 Millions Visit TAK's Balance sheet
Takeda Pharmaceutical Limited's Cash & cash equivalent $ 2,554 Millions Visit TAK's Balance sheet
Source of TAK's Sales Visit TAK's Sales by Geography


Cumulative Takeda Pharmaceutical Limited's Quick Ratio

TAK's Quick Ratio for the trailling 12 Months

TAK Quick Ratio

 (Mar 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Mar 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -10.41 % -4.36 % -7.83 % -1.7 % 4.68 %
Y / Y Cash & cash equivalent TTM Growth -21 % -18.84 % -27.33 % -25.34 % -23.48 %
Quick Ratio TTM 0.09 0.09 0.1 0.1 0.1
Total Ranking TTM # 3511 # 3802 # # #
Seq. Current Liabilities TTM Growth -4.41 % 2.18 % -4.31 % -4.14 % 2.04 %
Seq. Cash & cash equivalent TTM Growth -6.61 % -4.76 % -5.92 % -5.59 % -4.06 %

Quick ratio ranking by company, industry and sector >> Back to TAK Financial Strength Comparisons >> Go to Compare TAK Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in TAK's Current Liabilities to $28,661.03 millions, cumulative Quick Ratio to 0.09 below the TAK average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 454 other companies have achieved higher Quick Ratio than Takeda Pharmaceutical Limited. While Quick Ratio overall ranking has improved so far to 3511, from total ranking during the twelve months ending third quarter 2025 at 3802.

Explain Quick Ratio?
How much Cash & cash equivalents TAK´s has?
What are TAK´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 455
Healthcare Sector # 939
Within the Market # 3511


trailing twelve months Quick Ratio Statistics
High Average Low
0.2 0.16 0.1
(Mar 31 2022)   (Mar 31 2024)




Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2025 MRQ Cash & cash equivalentMar 31 2025 MRQ Current Liabilities
Cytodyn inc   0.23 $ 16.400  Millions$ 70.565  Millions
Organigram Global Inc   0.22 $ 21.601  Millions$ 96.638  Millions
Intercure Ltd   0.22 $ 46.466  Millions$ 214.365  Millions
Organon and Co   0.21 $ 547.000  Millions$ 2,615.000  Millions
Redhill Biopharma Ltd   0.21 $ 3.971  Millions$ 19.221  Millions
Jaguar Health Inc   0.20 $ 5.690  Millions$ 28.208  Millions
Lifecore Biomedical Inc   0.20 $ 5.417  Millions$ 27.150  Millions
Adlai Nortye Ltd  0.19 $ 8.056  Millions$ 41.628  Millions
Ernexa Therapeutics Inc   0.18 $ 1.918  Millions$ 10.438  Millions
Igc Pharma Inc   0.18 $ 0.405  Millions$ 2.257  Millions
Eli Lilly And Company  0.17 $ 3,220.700  Millions$ 18,517.800  Millions
Nrx Pharmaceuticals Inc   0.17 $ 5.548  Millions$ 32.751  Millions
REGENEREX PHARMA, INC.  0.17 $ 0.653  Millions$ 3.864  Millions
Biofrontera Inc   0.16 $ 1.785  Millions$ 10.959  Millions
Cv Sciences Inc   0.16 $ 0.812  Millions$ 5.112  Millions
Aspire Biopharma Holdings Inc   0.15 $ 1.347  Millions$ 8.869  Millions
Teva Pharmaceutical Industries Limited  0.15 $ 1,697.000  Millions$ 11,197.000  Millions
Novo Nordisk A  0.15 $ 4,920.176  Millions$ 33,887.650  Millions
Akari Therapeutics Plc  0.14 $ 2.582  Millions$ 18.123  Millions
Abbvie Inc   0.14 $ 5,176.000  Millions$ 36,403.000  Millions
Zyversa Therapeutics Inc   0.13 $ 1.612  Millions$ 12.004  Millions
Apimeds Pharmaceuticals US, Inc.  0.13 $ 0.250  Millions$ 1.870  Millions
IMPACT BIOMEDICAL INC.  0.13 $ 1.318  Millions$ 9.973  Millions
Viatris Inc   0.13 $ 755.000  Millions$ 5,720.100  Millions
Citius Pharmaceuticals Inc   0.12 $ 6.089  Millions$ 51.843  Millions
Gsk Plc  0.12 $ 4,754.859  Millions$ 41,130.339  Millions
Casi Pharmaceuticals inc   0.11 $ 5.632  Millions$ 49.670  Millions
Dr Reddy s Laboratories Limited  0.11 $ 172.000  Millions$ 1,527.000  Millions
Blue Water Vaccines Inc  0.11 $ 1.577  Millions$ 14.039  Millions
Takeda Pharmaceutical Company Limited  0.09 $ 2,553.695  Millions$ 28,661.027  Millions

Date modified: 2026-07-07T13:58:33+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.